Atlas Venture Life Science Advisors, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001917529

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 15 positions · Total reported value $949.64M · Top-10 concentration 97.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 55.6% · 2 new · 3 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.8% · vs SPY -13.9% · Prev Value $881.29M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +13.7% · vs SPY +11.5% · Latest Value $631.19M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2024 13F filing, Atlas Venture Life Science Advisors, LLC disclosed 15 equity positions with a combined reported value of $949.64M. The filing implies a focused portfolio: its ten largest positions account for 97.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were DYN ($283.03M), KYMR ($159.71M), THRD ($141.80M). By sector, the heaviest allocations are Health Care 69.6%, Other 30.4%. Versus the prior quarter, allocation shifted toward Health Care (+0.6pp) and away from Other (-0.6pp).

Versus the prior quarter, Atlas Venture Life Science Advisors, LLC opened 2 new positions, trimmed 3 and fully exited 0, a turnover rate of 55.6% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q2 2024 were TECX ($6.23M).

Of the 2 positions fully exited versus the prior quarter, the largest were AVRO ($5.81M), XLO ($1.07M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • TECX TECTONIC THERAPEUTIC INC · $6.23M

Fully Exited (vs previous quarter)

  • AVRO AVROBIO INC · prev qtr: $5.81M
  • XLO XILIO THERAPEUTICS INC · prev qtr: $1.07M

Insider Transactions (Form 4)

Latest Atlas Venture Life Science Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Atlas Venture Life Science Advisors, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 7 US equity positions with a combined value of $881.29M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 7 positions · $881.29M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: KYMR (KYMERA THERAPEUTICS INC) at 37.1%
  • Average position size: $125.90M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 added, 3 reduced
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 69.6%
Other 30.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.02M $283.03M 29.80%
29.80%
Hold
2 5.35M $159.71M 16.82%
16.82%
Reduce
3 10.91M $141.80M 14.93%
14.93%
Hold
4 2.51M $113.10M 11.91%
11.91%
Add
5 6.43M $88.61M 9.33%
9.33%
Hold
6 1.14M $38.52M 4.06%
4.06%
Add
7 2.09M $37.55M 3.95%
3.95%
Hold
8 8.28M $23.35M 2.46%
2.46%
Hold
9 5.84M $23.35M 2.46%
2.46%
Hold
10 2.10M $18.88M 1.99%
1.99%
Hold
11 5.02M $8.28M 0.87%
0.87%
Hold
12 378.45K $6.23M 0.66%
0.66%
New
13 136.98K $3.55M 0.37%
0.37%
Reduce
14 1.80M $2.99M 0.32%
0.32%
Reduce
15 535.34K $695.94K 0.07%
0.07%
Reduce

FAQ

What did Atlas Venture Life Science Advisors, LLC buy in 2024-Q2?

In its 2024-Q2 13F filing, Atlas Venture Life Science Advisors, LLC reported 15 equity positions worth $949.64M in aggregate; its largest disclosed positions were DYN ($283.03M), KYMR ($159.71M), THRD ($141.80M).

How large is Atlas Venture Life Science Advisors, LLC's portfolio?

Atlas Venture Life Science Advisors, LLC reported $949.64M of long equity holdings across 15 positions as of 2024-Q2. Top-10 holdings account for 97.7% of reported value.

What is Atlas Venture Life Science Advisors, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/atlas-venture-life-science-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →